Glenmark Specialty S.A. has secured DCGI approval to initiate patient enrollment in India for a Phase 3 trial of Trastuzumab rezetecan (SHR-A1811) for platinum-resistant ovarian cancer.

India

Who

Glenmark Specialty S.A., Glenmark Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals, DCGI

What

When

Thu, 02 Jul 2026 03:16:20 GMT · 1h 58m ago

Where

India ·

Why

To conduct a Phase 3 trial for Trastuzumab rezetecan for platinum-resistant ovarian cancer.

The Frontline Impact

How this affects you

India becomes the first licensed market for Glenmark to begin enrollment in this Phase 3 trial. The drug, Trastuzumab rezetecan, has previously achieved regulatory milestones in China and received NMPA Breakthrough Therapy Designation for multiple indications.

Story chain

1 event in this thread

No related history yet - this is the origin event.

Verified Sources & Citations

scanx.trade
https://scanx.trade/stock-market-news/companies/glenmark-advances-phase-3-trial-for-ovarian-cancer-drug/44507739
HIGH

Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.